We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

7 hedge funds and large institutions have $4.82M invested in ProShares UltraShort NASDAQ Biotechnology in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,100% more capital invested

Capital invested by funds: $43K → $4.82M (+$4.77M)

600% more funds holding

Funds holding: 1 → 7 (+6)

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

51% less call options, than puts

Call options by funds: $1.38M | Put options by funds: $2.79M

Holders
7
Holders Change
+6
Holders Change %
+600%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
–
Closed
1
Calls
$1.38M
Puts
$2.79M
Net Calls
-$1.41M
Net Calls Change
-$1.41M

Top Buyers

Rank Fund Capital Flow
1
HVC
Healthcare Value Capital
New Jersey
+$2.09M
2
BGA
Belmont Global Advisors
Texas
+$834K
3
CANY
Caxton Associates (New York)
New York
+$834K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$440K
5
SM
Southport Management
Wyoming
+$250K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$43K

BIS Hedge Fund Activity: Q1 2014 in Review

7 of the 3,456 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2014, worth a combined $4.82M — up 11,100% from $43K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BIS positions and 1 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Healthcare Value Capital, opening a new position worth an estimated $2.09M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $43K sold.

  • 7 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2014, up from 1 in Q4 2013.
  • Funds reported $4.82M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2014, up 11,100% quarter-over-quarter.
  • 7 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2014 and 1 closed out, a net change of +6 holders.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2014 was Healthcare Value Capital, an estimated $2.09M added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2014 was Tower Research Capital (TRC), an estimated $43K sold.

Based on aggregated 13F filings for Q1 2014.